Association of N-acetyltransferase 1 Polymorphism and Bladder Cancer Risk: An Updated Meta-analysis and Trial Sequential Analysis

No abstract is available for this paper.

• Publication year

  2017

• Venue

  International Journal of Biological Markers

• Publication date

  2017-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.5301/ijbm.5000269PMID 28604993
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cancer statistics, 2016

  2016cited by this paper
• Clearing the Air: Summarizing the Smoking-related Relative Risks of Bladder and Kidney Cancer.

  2016cited by this paper
• Association between DAZL polymorphisms and susceptibility to male infertility: systematic review with meta-analysis and trial sequential analysis

  2014cited by this paper
• The Impact of Study Size on Meta-analyses: Examination of Underpowered Studies in Cochrane Reviews

  2013cited by this paper
• Trial sequential analysis has the potential to improve the reliability of conclusions in meta-analysis.

  2013cited by this paper
• N-Acetyltransferase 1 (NAT1) Genotype: A Risk Factor for Urinary Bladder Cancer in a Lebanese Population

  2012cited by this paper
• Hair dye use and risk of bladder cancer in the New England bladder cancer study

  2011cited by this paper
• Apparently conclusive meta-analyses may be inconclusive--Trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses.

  2009cited by this paper
• Bmc Medical Research Methodology Open Access Estimating Required Information Size by Quantifying Diversity in Random-effects Model Meta-analyses

  2009cited by this paper
• Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses?

  2009cited by this paper
• Genetic determinants in the metabolism of bladder carcinogens in relation to risk of bladder cancer.

  2008cited by this paper
• Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis.

  2008cited by this paper
• Bladder cancer, GSTs, NAT1, NAT2, SULT1A1, XRCC1, XRCC3, XPD genetic polymorphisms and coffee consumption: a case–control study

  2008cited by this paper
• Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses.

  2008cited by this paper
• NAT2 Slow Acetylation, GSTM1 Null Genotype, and Risk of Bladder Cancer: Results from the Spanish Bladder Cancer Study and Meta-Analyses

  2006cited by this paper
• Polymorphisms in GSTT1, GSTM1, NAT1 and NAT2 genes and bladder cancer risk in men and women

  2006cited by this paper
• NAT2 slow acetylation and bladder cancer in workers exposed to benzidine

  2006cited by this paper
• Bias in clinical intervention research.

  2006cited by this paper
• Hair dye use is not associated with risk for bladder cancer: evidence from a case-control study in Spain.

  2006cited by this paper
• How strong is the evidence for the use of perioperative β blockers in non-cardiac surgery? Systematic review and meta-analysis of randomised controlled trials

  2005cited by this paper
• Effects of N-acetyl transferase 1 and 2 polymorphisms on bladder cancer risk in Caucasians.

  2005cited by this paper
• NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses.

  2005cited by this paper
• GST, NAT, SULT1A1, CYP1B1 genetic polymorphisms, interactions with environmental exposures and bladder cancer risk in a high‐risk population

  2004cited by this paper
• Absence of evidence is not evidence of absence

  2004cited by this paper
• Correlation of the genotypes for N-acetyltransferases 1 and 2 with double bladder and prostate cancers in a case-comparison study.

  2002cited by this paper
• Association of NAT1 and NAT2 polymorphisms to urinary bladder cancer: significantly reduced risk in subjects with NAT1*10.

  2001cited by this paper
• Genetic variability in susceptibility and response to toxicants.

  2001cited by this paper
• Genetic variability in susceptibility and response to toxicants.

  2001cited by this paper
• Association of arylamine N-acetyltransferase (NAT1 and NAT2) genotypes with urinary bladder cancer risk.

  2001cited by this paper
• Association of NAT 1 and NAT 2 Polymorphisms to Urinary Bladder Cancer : Significantly Reduced Risk in Subjects with NAT 1 * 10 1

  2001cited by this paper
• Genetic polymorphisms of N-acetyltransferase 1 and 2 and risk of cigarette smoking-related bladder cancer

  1999cited by this paper
• Arylamine N-acetyltransferase 1 (NAT1) and 2 (NAT2) genes and risk of urothelial transitional cell carcinoma among Japanese.

  1999cited by this paper
• Overcoming the limitations of current meta-analysis of randomised controlled trials.

  1998cited by this paper
• The role of N-acetylation polymorphisms in smoking-associated bladder cancer: evidence of a gene-gene-exposure three-way interaction.

  1998cited by this paper
• Bias in meta-analysis detected by a simple, graphical test

  1997cited by this paper
• Identification of a novel allele at the human NAT1 acetyltransferase locus.

  1997cited by this paper
• Cumulating evidence from randomized trials: utilizing sequential monitoring boundaries for cumulative meta-analysis.

  1997cited by this paper
• Arylamine N-acetyltransferase 1 (NAT1) and 2 (NAT2) polymorphisms in susceptibility to bladder cancer: the influence of smoking.

  1997cited by this paper
• Polymorphism in the N-acetyltransferase 1 (NAT1) polyadenylation signal: association of NAT1*10 allele with higher N-acetylation activity in bladder and colon tissue.

  1995cited by this paper
• Metabolic activation and deactivation of arylamine carcinogens by recombinant human NAT1 and polymorphic NAT2 acetyltransferases.

  1993cited by this paper
• Individual variability in p-aminobenzoic acid N-acetylation by human N-acetyltransferase (NAT1) of peripheral blood.

  1993cited by this paper
• Human Arylamine N-Acetyltransferase Genes: Isolation, Chromosomal Localization, and Functional Expression

  1990cited by this paper
• Meta-analysis in clinical trials.

  1986cited by this paper
• Statistical aspects of the analysis of data from retrospective studies of disease.

  1959cited by this paper

• Genetic Polymorphisms Involved in Bladder Cancer: A Global Review

  2023cites this paper
• Functional expression of human arylamine N-acetyltransferase NAT1*10 and NAT1*11 alleles: a mini review.

  2018cites this paper
• Carcinogenic potential of arylamine N-acetyltransferase in Asian populations

  2018cites this paper